Company Overview and News

 
Macquarie's $100 a share milestone cheers ASX as Telstra lags

2017-11-27 theage.com.au
Shares started the week on a positive note on Monday, with Macquarie shares jumping over $100 for the first time, although losses for Telstra worked to limit upside for the benchmark.

 
Macquarie's $100 a share milestone cheers ASX as Telstra lags

2017-11-27 smh.com.au
Shares started the week on a positive note on Monday, with Macquarie shares jumping over $100 for the first time, although losses for Telstra worked to limit upside for the benchmark.

 
How to make wealth preservation easy

2017-11-04 lifestyle.inquirer.net
There’s a famous saying about death and taxes that I’m thinking of, except that those are two things I never like to think about. Thank goodness there is Sun Life of Canada, which can deal with that stuff.

 
Joey Samson for Red Charity Gala may just be ‘the best show yet’

2017-10-12 lifestyle.inquirer.net
This multitextured dress is a preview of Samson’s vow to “step up” for the Red Charity Gala’s big stage.

 
Indigenous activewear gears up for success

2017-05-23 smh.com.au
Producing running tights and fitness accessories decorated with Indigenous art, the 22-year-old has won the attention of some big names including Google.

 
Why retail companies are struggling: there are fewer shoppers going inside

2017-05-19 theage.com.au
Perhaps it's no wonder that retailers Oroton, RCG Corp, Adairs have downgraded their guidance twice this year, Myer and Harvey Norman shares have reached 1.5 year lows and The Reject Shop's shares have reached an 11-year low.

 
Why retail companies are struggling: there are fewer shoppers going inside

2017-05-19 smh.com.au
Perhaps it's no wonder that retailers Oroton, RCG Corp, Adairs have downgraded their guidance twice this year, Myer and Harvey Norman shares have reached 1.5 year lows and The Reject Shop's shares have reached an 11-year low.

 
Markets Live: Analysts target JB, Harvey

2017-05-10 theage.com.au
Shares are set for a positive start after oil prices jumped overnight, but much will again depend on how the big banks perform, while Citi analysts slash their forecasts for JB Hi-Fi and Harvey Norman.

 
Markets Live: Analysts target JB, Harvey

2017-05-10 smh.com.au
Shares are set for a positive start after oil prices jumped overnight, but much will again depend on how the big banks perform, while Citi analysts slash their forecasts for JB Hi-Fi and Harvey Norman.

 
ASX see-saws higher as US avoids government shutdown

2017-05-01 theage.com.au
The ASX shrugged off a lacklustre start to rise strongly on a US spending deal that sent Wall Street futures solidly higher. 

 
ASX see-saws higher as US avoids government shutdown

2017-05-01 smh.com.au
The ASX shrugged off a lacklustre start to rise strongly on a US spending deal that sent Wall Street futures solidly higher. 

 
RCG cuts profit guidance 11pc as footwear sales soften

2017-05-01 theage.com.au
Footwear retailer RCG Corp has slashed full-year profit guidance by 11 per cent – the second downgrade in three months – after sales of brands such as Skechers, Vans and Doc Martens remained weak in March and April.

 
RCG cuts profit guidance 11pc as footwear sales soften

2017-05-01 smh.com.au
Footwear retailer RCG Corp has slashed full-year profit guidance by 11 per cent – the second downgrade in three months – after sales of brands such as Skechers, Vans and Doc Martens remained weak in March and April.

 
Shoes giant RCG cuts guidance on 'challenging' conditions

2017-02-24 theage.com.au
Shares in Australia's largest footwear business RCG Corp have slumped to a one-year low after it downgraded its full-year guidance by up to 5.6 per cent due to "challenging trading conditions since Boxing Day".

 
Shoes giant RCG cuts guidance on 'challenging' conditions

2017-02-24 smh.com.au
Shares in Australia's largest footwear business RCG Corp have slumped to a one-year low after it downgraded its full-year guidance by up to 5.6 per cent due to "challenging trading conditions since Boxing Day".

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...